Acute worsening of glycemic control in a patient with type 2 diabetes and non‐small cell lung cancer after administration of lorlatinib

A patient with non‐small cell lung cancer (NSCLC) exhibited extreme hyperglycemia after lorlatinib treatment. The present case highlights the importance of glucose monitoring during lorlatinib administration and intensifying hyperglycemia treatment.

Detalles Bibliográficos
Autores principales: Nakano, Yoshio, Miyasato‐Isoda, Mai, Gohma, Iwao, Fujisawa, Tomomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777166/
https://www.ncbi.nlm.nih.gov/pubmed/35079389
http://dx.doi.org/10.1002/ccr3.5283
Descripción
Sumario:A patient with non‐small cell lung cancer (NSCLC) exhibited extreme hyperglycemia after lorlatinib treatment. The present case highlights the importance of glucose monitoring during lorlatinib administration and intensifying hyperglycemia treatment.

Ejemplares similares